Archive · 3 Aug 2026
GlaxoSmithKline Posts 15.7% Profit Rise in Q1 FY27
GlaxoSmithKline Pharmaceuticals made more money in the first part of its 2026-27 year than it did last year.
It earned ₹237.18 crore, which is 15.7% more than the ₹205.01 crore it earned a year earlier.
The company also made more money from selling its products, earning ₹938.44 crore this quarter.
The people who help run the company changed a bit: Subesh Williams left the board, and Karine J F Natland joined.
The boss, Bhushan Akshikar, will keep his job as Managing Director for two more years.
Net profit rose 15.7% to ₹237.18 crore in Q1 FY27.
Revenue from operations increased to ₹938.44 crore from ₹805.17 crore.
EPS after exceptional items climbed to ₹14.00 from ₹12.10.
Subesh Williams resigned as Non‑Executive Director; Karine J F Natland appointed.
Bhushan Akshikar re‑appointed Managing Director for a two‑year term.
- Who
- GlaxoSmithKline Pharmaceuticals, its board members and executives
- What
- Q1 FY27 financial results and board changes
- When
- Quarter ended 30 June 2026; announced 3 August 2026
- Where
- Mumbai, India
- Why
- To inform investors of performance and governance changes
- Net Profit
- ₹237.18 crore
- Revenue from Operations
- ₹938.44 crore
- EPS (after exceptional items)
- ₹14.00
- Quarter Ended
- 30 June 2026
- Announcement Date
- 3 August 2026